ISSCR Conference

ReNeuron Group plc
15 June 2007

Millipore Corporation to promote ReNeuron's ReNcell(R) neural stem cell lines at
leading international stem cell conference



Guildford, UK, 15 June 2007: ReNeuron Group plc (LSE: RENE.L) today announces
that US-based Millipore Corporation, the exclusive distributor of ReNeuron's
ReNcell(R)CX and ReNcell(R)VM neural cell lines, will highlight characteristics
of the cell lines in a presentation to be given by Dr Vi Chu,  Millipore
Bioscience Division, at the 5th International Society for Stem Cell Research
(ISSCR) Annual Meeting in Cairns, Australia on 17-20 June.  The presentation is
scheduled for 08:00 am local time on 20 June.



The ReNcell(R) neural cell lines are being marketed through Millipore
Corporation's reagent catalogue as drug discovery tools for academic and
commercial research.  ReNeuron recently announced the publication of data
describing the characteristics of these cell lines in the on-line journal BMC
Neuroscience, generated in collaboration with the Department of Physiology,
University College London.



Further information relating to the ISSCR meeting may be found at www.isscr.org/
meetings.



Enquiries:


ReNeuron
Michael Hunt, Chief Executive Officer                 Tel: [phone]
Dr John Sinden, Chief Scientific Officer


Financial Dynamics
David Yates                                          Tel: [phone]
Nicola Daley



About ReNeuron



ReNeuron is a leading, UK-based stem cell therapy business.  It is applying its
novel stem cell platform technologies in the development of ground-breaking stem
cell therapies to serve significant and unmet or poorly-met clinical needs.



ReNeuron has used its c-mycER technology to generate genetically stable neural
stem cell lines.  This technology platform has multi-national patent protection
and is fully regulated by means of a chemically-induced safety switch.  Cell
growth can therefore be completely arrested prior to in vivo implantation.



ReNeuron has filed for approval to commence initial clinical studies in the US
with its lead ReN001 stem cell therapy for chronic stroke disability.  This
represents the world's first such filing concerning a neural stem cell treatment
for a major neurological disorder.  There are an estimated 50 million stroke
survivors worldwide, approximately one half of which are left with permanent
disabilities.  The annual health and social costs of caring for these patients
is estimated to be in excess of £5 billion in the UK and in excess of US$50
billion in the US.



ReNeuron has also generated pre-clinical efficacy data with its ReN005 stem cell
therapy for Huntington's disease, a genetic and fatal neurodegenerative disorder
that affects around 1 in 10,000 people.  This programme is in pre-clinical
development.  In addition to its stroke and Huntington's disease programmes,
ReNeuron is developing stem cell therapies for Parkinson's disease, Type 1
diabetes and diseases of the retina.



ReNeuron has also leveraged its stem cell technologies into non-therapeutic
areas - its ReNcell(R) range of cell lines for use in research and in drug
discovery applications in the pharmaceutical industry.  ReNeuron's ReNcell(R)CX
and ReNcell(R)VM neural cell lines are marketed worldwide under license by
Millipore Corporation.



ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.



Further information on ReNeuron and its products can be found at
www.reneuron.com.



Data sources: UK Stroke Association; American Stroke Association.



About Millipore Corporation



Millipore is a leading provider of products and services that improve
productivity in biopharmaceutical manufacturing and in clinical, analytical and
research laboratories.  The company is organized in two operating divisions.
Its Bioprocess Division helps enables pharmaceutical and biotechnology companies
to optimize their manufacturing productivity, ensure the quality of drugs, and
scale up the production of difficult-to-manufacture biologics.  Its Bioscience
division helps to optimize laboratory productivity and workflows. Its products
and enabling technologies that are used in the laboratory are essential for the
research and development of biologically based life science therapeutics.



Millipore has a deep understanding of its customers' research and manufacturing
process needs, and offers reliable and innovative tools, technologies and
services.  The company is part of the S&P 500 index and employs approximately
5,800 employees in more than 47 offices worldwide.  For additional information
on Millipore Corporation, please visit its website at www.millipore.com.



This announcement contains forward-looking statements with respect to the
financial condition, results of operations and business achievements/performance
of ReNeuron and certain of the plans and objectives of management of ReNeuron
with respect thereto. These statements may generally, but not always, be
identified by the use of words such as 'should', 'expects', 'estimates',
'believes' or similar expressions. This announcement also contains
forward-looking statements attributed to certain third parties relating to their
estimates regarding the growth of markets and demand for products. By their
nature, forward-looking statements involve risk and uncertainty because they
reflect ReNeuron's current expectations and assumptions as to future events and
circumstances that may not prove accurate.  A number of factors could cause
ReNeuron's actual financial condition, results of operations and business
achievements/performance to differ materially from the estimates made or implied
in such forward-looking statements and, accordingly, reliance should not be
placed on such statements.



The terms 'ReNeuron', 'the Company' or 'the Group' used in this statement refer
to ReNeuron Group plc and/or its subsidiary undertakings, depending on the
context.




                      This information is provided by RNS
            The company news service from the London Stock Exchange